EPA Let Bayer Choose From 3 Dicamba Rule Options, Files Show

Internal Environmental Protection Agency documents released in ongoing litigation show the agency asked Bayer to choose from a menu of regulatory options for dicamba, then incorporated the company's selections into a proposed federal rule, The Guardian reported on Sept. 20. The records offer a rare public view into pesticide rulemaking, a process typically conducted out of sight of regulators' usual public comment procedures.

What do the documents show about the EPA's process?

According to the Guardian's review of the records, the EPA presented Bayer with a range of mitigation options meant to limit dicamba's volatility and tendency to drift off target fields. One agency presentation ended with a slide titled "Registrant response needed," posing the question "Which mitigation option to go forward with?" Bayer answered, and the agency subsequently wrote those choices into a proposed rule, the documents show. The Guardian described the exchange as an unusually direct example of an interaction that is normally hidden from public view, even though negotiation between industry and the EPA is a routine part of pesticide regulation.

How did the EPA solicit Bayer's input on volatility limits?

The agency offered Bayer a range of options running from more protective to less protective, according to the records cited by the Guardian. The choices covered restrictions intended to reduce dicamba runoff and the compound's tendency to volatilize and drift after application — the property blamed for damage to neighboring fields not sprayed with the herbicide. The documents do not specify, in the reporting reviewed, how many total regulatory categories the EPA offered beyond the volatility and runoff provisions described.

What did Bayer choose, and what did it get?

Bayer selected the least protective of the offered options for one of the regulations and the middle tier among three levels of protection for a second, the Guardian reported. The company also secured one additional change it had requested incorporated into the rule. The Guardian's account does not identify a named EPA or Bayer scientist explaining the technical basis for the tiers, and no researcher assessment of the selected options' effectiveness at reducing drift was cited in the documents as reported.

What are the documented health and environmental risks tied to dicamba?

Dicamba is described in the reporting as drift-prone, capable of killing vegetation and crops for miles beyond the fields where it is sprayed. It has been linked to liver cancer and Non-Hodgkin lymphoma, according to the Guardian's report, though the article does not cite a specific study, sample size, or research institution behind that association. The absence of a named study underscores a limit in what can be verified from this reporting alone: the health-risk claim is stated as established fact in the source material without an accompanying citation to primary epidemiological data.

What has the regulatory and legal history been?

Courts have twice ordered dicamba off the market over its drift problems, according to the Guardian, and the EPA has re-approved the herbicide both times. The newly disclosed documents surfaced through ongoing litigation over the substance, though the Guardian's report does not name the specific case, court, or plaintiffs involved, nor does it specify a docket number or filing date for the records.

What should be watched next?

The documents were produced through litigation still underway, meaning additional records or rulings could surface as the case proceeds. Anyone following the dispute should watch for: whether the EPA responds publicly to the disclosure; whether a court weighs the Bayer-EPA exchange in evaluating the current dicamba rule's legality, given the herbicide's two prior market removals; and whether Bayer or the EPA releases a fuller account of the mitigation options presented, since the reporting describes only two of the regulatory choices in detail. The Guardian's report does not indicate a timeline for further rulings or agency action, and no comment from Bayer or the EPA is quoted in the material reviewed. Readers seeking the underlying records should consult the litigation docket referenced in the original reporting once it becomes available, since the documents themselves were not published in full alongside the article.